Somapacitan LA is under clinical development by Novo Nordisk and currently in Phase III for Born Small For Gestational Age (SGA). According to GlobalData, Phase III drugs for Born Small For Gestational Age (SGA) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Somapacitan LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Somapacitan LA overview
Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).
Somapacitan (NNC0195-0092) is under development for the treatment of growth hormone deficiency, born small for gestational age,Turner Syndrome, Noonan Syndrome, and idiopathic short stature. The drug candidate is administered subcutaneously as a solution. It acts by targeting somatotropin receptor. It is a long-acting albumin-binding growth hormone derivative.
Novo Nordisk overview
Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
For a complete picture of Somapacitan LA’s drug-specific PTSR and LoA scores, buy the report here.